Inge Marie Svane

Inge Marie Svane

Clinical Professor

Member of:

  • Clinical Oncology


  1. Published

    T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy

    Andersen, R., Westergaard, M. C. W., Kjeldsen, J. W., Müller, A., Pedersen, N. W., Hadrup, S. R., Met, Özcan, Seliger, B., Kromann-Andersen, B., Hasselager, T., dqp123, dqp123 & Svane, Inge Marie, 2018, In: Cancer Immunology Research. 6, 2, p. 222-235 14 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Published

    Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab

    Andersen, R., Nørgaard, P. H., Al-Jailawi, M. K. M. & Svane, Inge Marie, 23 Jan 2014, In: OncoImmunology. 3, 8, e954506.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Identification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors

    Andersen, R. S., Sørensen, R. B., Ritter, C., Svane, Inge Marie, Becker, J. C., thor Straten, P. & Andersen, Mads Hald, 2011, In: Cancer Immunology, Immunotherapy. 60, 2, p. 227-34 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Dissection of T-cell antigen specificity in human melanoma

    Andersen, R. S., Albæk Thrue, C., Junker, N., Skou, R. B. L., Donia, M., Ellebæk, E., Svane, Inge Marie, Schumacher, T. N., Thor Straten, P. & Hadrup, S. R., 2012, In: Cancer Research. 72, 7, p. 1642-50 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome

    Araujo B de Lima, V., Borch, A., Hansen, M., Draghi, A., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, Apr 2020, In: Cytotherapy. 22, 4, p. 204-213 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

    Araujo B. de Lima, V., Hansen, M., Spanggaard, I., Rohrberg, K., Reker Hadrup, S., Lassen, Ulrik Niels & Svane, Inge Marie, 25 Mar 2021, In: Frontiers in Oncology. 11, 11 p., 558248.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

    Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Ny, L. & 8 others, Arance, A., Svane, Inge Marie, Schadendorf, D., Gogas, H., Saci, A., Jiang, J., Rizzo, J. & Atkinson, V., 2019, In: JAMA Oncology. 5, 2, p. 187-194

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

    Ascierto, P. A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., Lebbé, C., Bastholt, L., Hamid, O., Rutkowski, P., McNeil, C., Garbe, C., Loquai, C., Dreno, B., Thomas, L., Grob, J-J., Liszkay, G., Nyakas, M., Gutzmer, R., Pikiel, J. & 10 others, Grange, F., Hoeller, C., Ferraresi, V., Smylie, M., Schadendorf, D., Mortier, L., Svane, Inge Marie, Hennicken, D., Qureshi, A. & Maio, M., May 2017, In: Lancet Oncology. 18, 5, p. 611-622 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st–2nd, 2021

    Ascierto, P. A., Avallone, A., Bhardwaj, N., Bifulco, C., Bracarda, S., Brody, J. D., Buonaguro, L., Demaria, S., Emens, L. A., Ferris, R. L., Galon, J., Khleif, S. N., Klebanoff, C. A., Laskowski, T., Melero, I., Paulos, C. M., Pignata, S., Ruella, M., Svane, I. M., Taube, J. M. & 3 others, Fox, B. A., Hwu, P. & Puzanov, I., 2022, In: Journal of Translational Medicine. 20, 1, 257.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

    Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, Inge Marie, Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., 2019, In: Nature Medicine. 25, 6, p. 941-946 6 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...28 Next

ID: 4054758